Light Chain Amyloidosis 2014

Research output: Contribution to journalArticlepeer-review


AL amyloidosis patients are difficult to diagnose. Patients having multi-organ and particularly cardiac involvement are considered to have bad prognosis. Early diagnosis is therefore essential. Treatment is to be given according to risk. The use of autologous stem cell transplantation is associated with unacceptable toxicity in high-risk patients. Low risk and some intermediate risk patients may benefit from it with responding patients having prolonged overall survival. New medications, such as thalidomide, lenalidomide and bortezomib, and next generation IMiDs and proteasome inhibitors are derived from multiple myeloma regimens. Their combination with dexamethasone and alkylating agents have a profound effect even in transplant ineligible patients.with surviving patients having excellent progression-free and overall survival, even in a significant proportion of high risk, poor prognosis populations. This review includes the latest updates on treatment for AL amyloidosis patients in 2014, in light of the progress done during the recent years.
Original languageAmerican English
Pages (from-to)21-29
Number of pages9
JournalInternational Journal of Hematological Disorders
Issue number1A
StatePublished - 2014


Dive into the research topics of 'Light Chain Amyloidosis 2014'. Together they form a unique fingerprint.

Cite this